In recent years, targeted drugs represented by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), such as gefitinib and erlotinib, have shown inspiring efficacy in the treatment of locally advanced and metastatic NSCLC, which specifically inhibit tumor cells with low side effects [30]. Here, EGFR is linked to neoplasm.